Glucotrack Inc. (NASDAQ: GCTK) announced the publication of a peer-reviewed study in The Journal of Diabetes Research demonstrating the performance of its continuous blood glucose monitoring technology over 240 days in sheep.

The study evaluated 34 devices implanted in 17 adult sheep over periods up to 240 days. Results showed a weighted average Mean Absolute Relative Difference of 6.8% across 79 intravenous glucose tolerance tests conducted during the study period. The devices maintained glucose sensing performance with no device-related adverse safety events observed.

"The publication of this peer-reviewed study in the Journal of Diabetes Research provides externally validated evidence of the long-term performance of our CBGM technology," said Dr. Paul V. Goode, President and Chief Executive Officer of Glucotrack. "Sustained accuracy and consistent device performance over 240 days in a preclinical model reinforces our confidence in the platform's design."

The company's continuous blood glucose monitoring system is designed as a long-term implantable device with a sensor longevity of three years and no on-body wearable component. Previous first-in-human clinical study data showed a MARD of 7.7% with a 99% data capture rate and no procedure- or device-related serious adverse events.

Glucotrack is developing the technology for people with diabetes. The device remains investigational and is limited to investigational use under federal law. The company is preparing for an IDE submission with the FDA as part of its clinical development pathway.